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A B S T R A C T
Some oral manifestations have been observed in patients with coronavirus disease 2019 (COVID-19).
However, there is still a question about whether these lesions are due to coronavirus infection or
secondary manifestations resulting from the patient's systemic condition. Thus, this article aims to report
an additional case of an oral condition in a patient diagnosed with COVID-19. Our patient, a sixty-seven-
year-old Caucasian man, tested positive to coronavirus and presented oral manifestations such as
recurrent herpes simplex, candidiasis, and geographic tongue. We support the argument that some oral
conditions could be secondary to the deterioration of systemic health or due to treatments for COVID-19.
The present case report highlights the importance of including dentists in the intensive care unit multi-
professional team to improve oral health in critical patients, not only COVID-19 patients, but also, to
contribute to evidence-based and decision-making in managing infectious diseases.
© 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
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The novel coronavirus disease 2019 (COVID-19) presents an
important and urgent threat to global health. The novel coronavi-
rus was initially named 2019-nCoV and officially as severe acute
respiratory syndrome coronavirus 2 (SARS- CoV-2) (WHO, 2020).
The lungs are the primary site of infection for COVID-19, with
patients presenting symptoms ranging from mild flu-like symp-
toms to fulminant pneumonia and potentially lethal respiratory
distress (Guan et al., 2020).
There have been some COVID-19 cases reporting oral manifes-
tations (Chaux-Bodard et al., 2020; de Maria et al., 2020; Lechien
et al., 2020; Martín Carreras-Presas et al., 2020; Putra et al., 2020).
Since the oral health of COVID-19 patients can be affected by the
infection, there is still doubt whether these manifestations could
be a typical pattern resulting from the direct viral infection.
Perhaps oral lesions may result from systemic deterioration,
considering the possibility of opportunistic infections and also
adverse reactions to treatments. Therefore, the range of COVID-19
manifestations in the oral cavity has broad and current interest.
This brief article's overall objective was to report a relevant case of
oral manifestations in a COVID-19 patient.
Case report
On March 31, 2020, a sixty-seven-year-old Caucasian man with
a history of cruising the Brazilian coast in the past 30 days, was
admitted at Hospital Alvorada Brasília, Brasilia, Brazil. Ten days
earlier, the patient developed respiratory symptoms, progressivehttps://doi.org/10.1016/j.ijid.2020.06.012
1201-9712/© 2020 The Author(s). Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).dyspnea on exertion, and fever, and diarrhea. The patient was
asked about symptoms of gustatory and olfactory disfunction, and
he reported hypogeusia. In the medical history, the patient
reported coronary disease, already revascularized, systemic
hypertension, autosomal dominant polycystic kidney disease,
and kidney transplant, which led him to take immunosuppressants
regularly and to use pharmacological prophylaxis for pulmonary
venous thromboembolism with Enoxaparin sodium (Clexane1 20
mg/day). A nasopharyngeal swab following reverse-transcription
polymerase chain reaction (RT-PCR) for SARS-CoV-2 RNA amplifi-
cation tested positive. Chest computed tomography evidenced
bilateral diffuse hyperdense infiltrations in the so-called “ground
glass” pattern affecting both lungs, leading to intensive care unit
(ICU) admission for supplemental O2. After that, the patient
underwent orotracheal intubation due to disease progression and
respiratory failure, and the patient was treated with Hydroxy-
chloroquine sulfate (Reuquinol1, 400 mg/day), Ceftriaxone sodi-
um (2 g/day), and Azithromycin (Zitromax1 500 mg/day) for seven
days.
Due to clinical suspicion of pneumonia associated with
mechanical ventilation, and worsening of the white blood cell
count, a new antibiotic regimen was started with Meropeném
(Meronem1,1000 mg, 8/8 hs) and Sulfamethoxazole + Trimetropin
(Bactrim1, 400 mg + 80 mg, 1.5 ampule, 8/8 hs) for ten days. Then,
the patient underwent a tracheostomy. Hemodialysis was per-
formed with subsequent recovery of renal function. Mechanical
ventilation was maintained with good recovery and the possibility
of spontaneous breathing. The patient also returned to the use of
immunosuppressants and pharmacological prophylaxis for venousciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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(Clexane1 60 mg/day).
On the twenty-fourth day of hospitalization, the dentists (RLC S
and RMP) were called to assess a persistent white plaque on the
tongue dorsum. This lesion was previously treated by physicians
with intravenous Fluconazole (Zoltec1 200 mg/100 mL, one bag a
day for ten days) and oral nystatin (100,000 IU/mL, 8/8 h, for 30
days), but no regression was observed. In addition to the white
plaque, the dentist also observed multiple pinpoint yellowish
ulcers on the tongue dorsum resembling the late stage of herpetic
recurrent oral lesions (Figure 1A). After a complete intraoral
examination, no other lesions on the oral mucosa were observed,
except for a nodule located in the lower lip, measuring
approximately 1 cm in its largest diameter, suggestive of a reactive
lesion (fibroma) that was confirmed by the patient’s pre-existing
conditions. Tongue scrape culture was performed, which was
compatible with Saccharomyces cerevisiae. Extremely viscous saliva
was observed; biopsies were not recommended due to the
patient’s systemic conditions. And, cutaneous lesions were not
observed during the patient’s physical examination. At this time,
the patient kept the antifungals and was treated with chlorhexi-
dine digluconate (0.12%) alcohol-free mouth rinses, and daily
applications of 1% hydrogen peroxide. The dentist also instructedFigure 1. (A) April 24, 2020. COVID-19 patient presenting a white plaque on the tongu
ulcers resembling the late stage of herpetic recurrent oral lesions associated with candidi
in its largest diameter, suggesting a reactive lesion (fibroma). (B) May 7, 2020. COVID-1
classified as severe geographic tongue according to the severity index scoring system (Pi
suggestive of candidiasis, showed almost complete resolution. (C) May 25, 2020. The pa
yellow-white halo classified as moderate geographic tongue according to the severity in
area in the right palatine tonsil region; however, the patient reported being asymptomthe health team on the importance of maintaining oral hygiene
care.
Two weeks after the first oral examination, the white lesions on
the tongue dorsum showed almost complete resolution. In a new
intraoral examination, it was observed that the patient presented
an asymptomatic geographic tongue classified as severe, according
to the severity index recently published (Picciani et al., 2020)
(Figure 1B), associated with fissured tongue.
The patient was discharged from the ICU, and in subsequent
days, there was a prompt recovery. The patient had no fever, and
the physician was able to gradually decrease oxygen flow,
discontinuing antibiotic therapies. At that moment, in a hospital
apartment, he was conscious, oriented, and not dependent on
oxygen therapy. Also, the patient had no complaints, preserved
appetite, good water consumption, good urine volume, and was
afebrile.
On May 14, the patient was discharged after forty-four days of
hospitalization; the dentist only prescribed oral health care. Ten
days later, the patient sent us an intraoral image in which
maintenance of geographic tongue could be observed, but it was
now classified as moderate, according to the severity index
recently published (Picciani et al., 2020). Also, a slightly
erythematous area could be seen in the right palatine tonsile dorsum, centrally located, associated with several small, circle-shaped yellowish
asis. A nodule located in the lower lip was observed, measuring approximately 1 cm
9 patient presenting atrophic areas surrounded by an elevated yellow-white halo
cciani et al., 2019) associated with fissured tongue. Also, the tongue’s white lesions,
tient, recovered from COVID-19, showing atrophic areas surrounded by an elevated
dex scoring system (Picciani et al., 2020). We could observe a slightly erythematous
atic.
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(Figure 1C).
Discussion
Current research shows that coronavirus damage to respiratory
and other organs could be related to the distribution of
angiotensin-converting enzyme 2 (ACE2) receptors in the human
system (Zou et al., 2020). Therefore, cells with ACE2 receptor
distribution may become host cells for the virus and further cause
inflammatory reactions in related organs and tissues, such as the
tongue mucosa and salivary glands (Xu et al., 2020). Besides,
available evidence has not established an efficient and safe
pharmacological agent against COVID-19 yet, and the potential
ones are related to several adverse reactions, including oral lesions
(Godinho et al., 2020; Mehra et al., 2020; de Melo Filho et al., 2012;
National Center for Biotechnology Information, 2020). Also,
COVID-19 acute infection, along with associated therapeutic
measures, could potentially contribute to adverse outcomes
concerning oral health, likely leading to various opportunistic
fungal infections, recurrent oral herpes simplex virus (HSV-1)
infection, unspecific oral ulcerations, fixed drug eruptions,
dysgeusia, xerostomia linked to decreased salivary flow, ulcer-
ations and gingivitis as a result of the impaired immune system
and/or susceptible oral mucosa(Dziedzic and Wojtyczka, 2020).
The oral conditions presented by our patient and other cases
already reported (Martín Carreras-Presas et al., 2020; Putra et al.,
2020) supports the hypothesis that they are highly suggestive of
secondary lesions resulting from the deterioration of systemic
health or due to treatments for COVID-19. Even considering our
interpretation of associated conditions, the dentist's relevance as
part of the multi-disciplinary team in supporting critical patients
in ICU, such as COVID-19, should be highlighted. Also, dental follow
up after the patient is dismissed from the hospital must be
provided. In COVID-19 patients we should consider the occurrence
of some oral signs and symptoms, including dysgeusia, petechiae,
candidiasis, traumatic ulcers, HSV-1 infection, geographical
tongue, thrush-like ulcers, among others. Thus, the importance
of the clinical dental examination of patients with infectious
diseases in the ICU should be emphasized, considering the need for
support, pain control, and quality of life.
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